Effect of Domperidone on QT Interval in Neonates

Journal of Pediatrics

Volumn 153, Issue 5, 2008, Pages 663-666

  Djeddi, Djamal ^a   Kongolo, Guy ^a   Lefaix, Charlotte ^a   Mounard, Julie ^a   Léké, André ^a  

^a Amiens School of Management   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOMPERIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; POTASSIUM;

ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; ELECTROLYTE DISTURBANCE; GASTROESOPHAGEAL REFLUX; HEART VENTRICLE ARRHYTHMIA; HUMAN; NEWBORN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; BLOOD; DRUG EFFECT; DRUG THERAPY; GESTATIONAL AGE; HEART ARRHYTHMIA; HEART CONTRACTION; INFANT; LONG QT SYNDROME; ORAL DRUG ADMINISTRATION; RISK; RISK FACTOR;

ADMINISTRATION, ORAL; ARRHYTHMIAS, CARDIAC; DOMPERIDONE; DOPAMINE ANTAGONISTS; DRUG THERAPY; GASTROESOPHAGEAL REFLUX; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; LONG QT SYNDROME; MYOCARDIAL CONTRACTION; POTASSIUM; RISK; RISK FACTORS;

EID: 55549088917     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2008.05.013     Document Type: Article

References (22)

1. Tahiri C. Prépulsid et allongement de l'espace QT. J Pédiatr Puériculture 11 (1998) 422-428
2. Lupoglazoff J.M., Bedu A., Faure C., Denjoy I., Casasoprana A., Cézard J.P., et al. Allongement de l'espace QT sous cisapride chez le nouveau-né et le nourrisson. Arch Pédiatr 4 (1997) 509-514
3. Hanson R., Browne G., Fasher B., Mcaskill M., Moroney P., and Hawker R. Cisapride-induced prolonged QT interval: too much of a good thing!. J Pediatr 130 (1997) 164-166
4. Wysowski D., and Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 335 (1996) 4
5. Abildskov J.A. The prolonged QT interval. Ann Rev Med 30 (1979) 171-179
6. Alimurung M., Joseph L., Graige E., and Massell B.F. The Q-T interval in normal infants and children. Circulation 1 (1950) 1329-1337
7. Lepeschkin E., and Surawicz B. The measurement of the QT interval of the Electrocardiogram. Circulation 6 (1952) 378-388
8. Savelieva I., Yi G., Guo X., Hnatkova K., and Malik M. Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. Am J Cardiol 81 (1998) 471-477
9. Rocha C., and Barbosa M. QT interval prolongation associated with the oral use of Dompéridone in an infant. Pediatr Cardiol 26 (2005) 720-723
10. Morganroth J. Relations of QTc prolongation on electrocardiogram to torsades de pointes: definitions and mechanisms. Am J Cardiol 72 (1993) 10B-13B
11. Bruera E., Villamayor R., Roca E., Barugel M., Tronge J., and Chacon R. QT interval prolongation and ventricular fibrillation with IV domperidone. Cancer Treat Rep 70 (1986) 545-546
12. Quinn N., Parkes D., Jackson G., and Upward J. Cardiotoxicity of domperidone. Lancet 2 (1985) 724
13. Wang S.H., Lin C.Y., Huang T.Y., Wu W.S., Chen C.C., and Tsai S.H. QT interval effects of cisapride in the clinical setting. Inter J Cardiol 80 (2001) 179-183
14. Drolet B., Rousseau G., Daleau P., Cardinal R., and Turgeon J. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102 (2000) 1883-1885
15. Zeltser D., Justo D., Halkin A., Prokhorov V., Heller K., and Viskin S. Torsade de pointes due to noncardiac drugs. Medicine 82 (2003) 282-290
16. Yang T., Snyders D., and Roden D. Drug block of Ikr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38 (2001) 737-744
17. Committee for Proprietary Medicinal Products. The Assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products (1997) 986-996
18. Heykants J., Hendriks R., Meuldermans W., Michiels M., Scheygrond H., and Reyntjens H. On the pharmacokinetics of domperidone in animals and man, IV: the pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 61 (1981) 61-70
19. Huizing G., Brouwers J.R., and Westhuis P. Plasma drug concentration and prolactin release after acute and subchronic oral administration of domperidone and metoclopramide: the serum concentration of drugs (1980) 271-277
20. Compton S.J., Lux R.L., Ramsey M.R., Strelich K.R., Sanguinetti M.C., Green L.S., et al. Genetically defined therapy of inherited long-QT syndrome: correction of abnormal repolarization by potassium. Circulation 94 (1996) 1018-1022
21. Dubin A., Kikkert M., Mirmiran M., and Ariagno R. Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics 107 (2001) 1313-1316
22. Zamora S.A., Belli D.C., Friedli B., and Jaeggi E. 24-hours electrocardiogram before and during cisapride treatment in neonates and infants. Biol Neonate 85 (2004) 229-236